Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBIT Margin (2016 - 2025)

Capricor Therapeutics has reported EBIT Margin over the past 15 years, most recently at 200103.71% for Q1 2025.

  • Quarterly results put EBIT Margin at 200103.71% for Q1 2025, down 20000105.0% from a year ago — trailing twelve months through Dec 2025 was 866176.45% (down 86602090.0% YoY), and the annual figure for FY2024 was 191.12%, down 9549.0%.
  • EBIT Margin for Q1 2025 was 200103.71% at Capricor Therapeutics, down from 69.15% in the prior quarter.
  • Over the last five years, EBIT Margin for CAPR hit a ceiling of 10.6% in Q4 2023 and a floor of 200103.71% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 349.43% (2022), compared with a mean of 15854.33%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 450397bps in 2021 and later tumbled -20000105bps in 2025.
  • Capricor Therapeutics' EBIT Margin stood at 2490.75% in 2021, then skyrocketed by 66bps to 840.33% in 2022, then skyrocketed by 99bps to 10.6% in 2023, then plummeted by -552bps to 69.15% in 2024, then plummeted by -289295bps to 200103.71% in 2025.
  • The last three reported values for EBIT Margin were 200103.71% (Q1 2025), 69.15% (Q4 2024), and 575.24% (Q3 2024) per Business Quant data.